Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistance

被引：1

作者：

Lin, Xixi ^{[1
,2
]}

Qiu, Ye ^{[1
,2
]}

Soni, Aashish ^{[1
,2
]}

Stuschke, Martin ^{[1
,3
]}

Iliakis, George ^{[1
,2
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Radiat Therapy, Div Expt Radiat Biol, D-45147 Essen, Germany

[2] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Radiat Biol, D-45147 Essen, Germany

[3] German Canc Res Ctr, Partner Site Univ Hosp Essen, German Canc Consortium DKTK, D-45147 Essen, Germany

来源：

MOLECULAR THERAPY ONCOLOGY | 2025年 / 33卷 / 01期

关键词：

STRAND-BREAK REPAIR; REPLICATION FORK STABILITY; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; LUNG-CANCER; CHECKPOINT; OLAPARIB; CELLS; PHOSPHORYLATION; DEGRADATION;

D O I：

10.1016/j.omton.2025.200934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of poly (ADP-ribose) polymerase inhibitors (PARPis) is widely considered a therapeutic milestone in the management of BRCA1/2-deficient malignancies. Since a growing number of cancer treatment guidelines include PARPis, the inevitably emerging PARPi resistance becomes a serious limitation that must be addressed. Targeting the DNA damage response signaling kinase, ATR (ataxia telangiectasia and rad3-related serine/threonine kinase), activated in response to PARPi-induced replication stress, represents a promising approach in fighting PARPi-resistant cancers. The success of this combination therapy in preclinical models has inspired efforts to translate its potential through extensive clinical research and clinical trials. However, the available clinical evidence suggests that PARPi/ATRi combinations have yet to reach their anticipated therapeutic potential. In this review, we summarize work elucidating mechanisms underpinning the effectiveness of ATRi in fighting PARPi resistance and review translational studies reporting efficacy in different types of cancer. Finally, we discuss potential biomarkers of patient selection for customized combinations of PARPi/ATRi treatments.

引用

页数：14

共 25 条

[21] HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2 [J].

Ho, Cassandra S. L. ;

Tuens, Alicia, I ;

Schildhaus, Hans-Ulrich ;

Wiesweg, Marcel ;

Gruener, Barbara M. ;

Hegedus, Balazs ;

Schuler, Martin ;

Schramm, Alexander ;

Oeck, Sebastian .

EUROPEAN JOURNAL OF CANCER, 2021, 159 :16-23

[22] Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy? [J].

Zaryouh, Hannah ;

Van Loenhout, Jinthe ;

Peeters, Marc ;

Vermorken, Jan Baptist ;

Lardon, Filip ;

Wouters, An .

CANCERS, 2022, 14 (24)

[23] RETRACTED: Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells (Retracted article. See vol. 40, 2019) [J].

Lai, I-Lu ;

Chou, Chih-Chien ;

Lai, Po-Ting ;

Fang, Chun-Sheng ;

Shirley, Lawrence A. ;

Yan, Ribai ;

Mo, Xiaokui ;

Bloomston, Mark ;

Kulp, Samuel K. ;

Bekaii-Saab, Tanios ;

Chen, Ching-Shih .

CARCINOGENESIS, 2014, 35 (10) :2203-2213

[24] Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery [J].

Jin, Hongyue ;

He, Yang ;

Zhao, Pengfei ;

Hu, Ying ;

Tao, Jin ;

Chen, Jiang ;

Huang, Yongzhuo .

THERANOSTICS, 2019, 9 (01) :265-278

[25] Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors [J].

Biegala, Lukasz ;

Kolat, Damian ;

Gajek, Arkadiusz ;

Pluciennik, Elzbieta ;

Marczak, Agnieszka ;

Sliwinska, Agnieszka ;

Mikula, Michal ;

Rogalska, Aneta .

CELLS, 2024, 13 (10)

← 1 2 3 →